Leading the race no one wants to win – a COVID-19 global case update

COVID-19 is on everyone’s mind these days as it appears it will be here — for an undeterminable amount of time. The various countries have had a wide range of responses, with some clearly being more effective than others. The one thing about this virus is it needs to be respected and until some sort of vaccine treatment becomes available, the only effective response is to wear a mask and keeping a social distance.

Looking at cases per million in the populations globally, Chile leads the 19 countries I am tracking with almost 18,000 cases per million, followed by the USA with nearly 13,000 per million. Neither country shows signs of slowing, as shown in the graph below. Peru and Brazil are also trending up at around 11,000 per million. Next, is Sweden, which is closing in on 8,000 per million. Spain, which had levelled off is seeing an uptick at 6,835 per million. Russia is climbing at 5,500 per million and India, due to its huge population is just starting the growth curve exhibited by all countries at 1,000 per million.

This said, I question both Russia’s and India’s numbers given limited testing in India is at 11,500 per million. And in reviewing Russia’s curve, the testing results are not showing the typical exponential growth. Perhaps this is due to how they classify cases since they are among the best in testing? Remember the USA? It took less than one month to move from 8,000 to almost 13,000 positive cases of COVID-19 per million. At this rate, the USA will break 18,000 cases per million before the end of August!

On the stat review of deaths per million, the UK is the unfortunate winner. The UK has 670 per million, followed by Spain with 608 per million. Italy, which had the world watching at the onset, has levelled off to 580 deaths per million. Other European countries such as Sweden, has 560 COVID-19 deaths per million, and France’s numbers average at 460 per million. These European countries are flattening the fatality curve, with Sweden being the last one to turn the corner, it is deemed to be heading in the right direction.

This group is being closely watched by four countries whose death toll trends are still escalating. These countries include Chile at 457 per million, the USA at 438 per million, Peru at 417 per million and Brazil at 390 deaths per million. Given this data is a lagging indicator, I expect these four to surpass France and grow to over 500 per million in the upcoming weeks. The only other country with over 350 deaths per million is the Netherlands. In reviewing my chart below, you will see that Canada kind of stands out by itself at 235 deaths per million. All the rest of the 19 countries I follow have less than 110 deaths per million.

In comparing the USA and Canada there are stark contrasts. Not saying that Canada has done a great job given it s slow response in nursing homes, but the charts below paint a different picture of two neighbors. The USA has 4.3% of the world’s population and has 26.7% of the world’s cases and a whopping 23.4% of the world’s deaths. Compare this to Canada, which has 0.5% of the world’s population, 0.7% of the world’s cases and 1.4% of the world’s deaths.

Let me know what you think of the data charts, and remember to respect the virus and stay safe — wear a mask.




MedX Health continues its global expansion in the fight against skin cancer

Skin cancer is the most common cancer in the United States and worldwide, but early screening can save lives. Did you know these gruesome facts?

  • One in every three cancers diagnosed is skin cancer.
  • Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year.
  • 1 in 5 Americans will develop skin cancer by the age of 70.
  • More than 2 people die of skin cancer in the U.S. every hour.

Clearly the world needs a much better early skin cancer screening technology.

MedX Health Corp. (TSXV: MDX) is a leading medical device and software company focused on the early detection of skin cancer. MedX has approvals in 35 countries and distribution agreements in place for its key skin cancer diagnostic products – SIAscope and DermSecure™ telemedicine platform.

Following on from MedX’s regulatory approval and distribution agreement in Brazil (read here), the Company recently announced an exciting exclusive distribution agreement to launch SIAscopy on DermSecure™ in Mexico with EMC LABS, S.A.P.I. DE C.V.operating as MedX Mexico. MedX Mexico plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform. MedX Mexico will cover all the upfront costs for application for regulatory approval in Mexico, all marketing costs, and will utilize their large-scale distribution network in Mexico.

MedX Mexico’s, President and CEO, Carlos Vizcaino, states:

“There is a significant opportunity for MedX’s rapid skin assessment technology in Mexico, as skin cancer is a very common type of cancer in Mexico……MedX’s SIAscopy on DermSecure™ Telemedicine platform and advanced SIAscopy imaging technology is a perfect solution to assist dermatologists and physicians in the diagnosis process for early detection of melanoma.”

Masterplan

MedX Health’s masterplan is to continue to rollout distribution agreements with partners globally. So far Brazil and now Mexico are underway. MedX’s revolutionary skin cancer detection device is approved in the USA, Canada, Brazil, Australia, New Zealand, the European Union, Turkey, and many other places. In total MedX’s device has achieved regulatory approval in 35 countries. This means we can expect further distribution agreements in the future to many of the above countries. The potential for future revenues is enormous.

MedX’s business model is similar to Software as a Service (SaaS) companies. The revenue model uses front-end hardware sales coupled with recurring “platform” revenue based on a minimum number of screens per device (360/year at $10/image).

2019 revenues were only small at C$860,248, and 1st quarter 2020 C$95,544, as the Company was impacted by COVID-19 and had yet to ramp up distribution as is now occurring in 2020. For a guide on where revenues are headed the next two years the Beacon Securities report is most useful.

The report’s analysts says MedX has strong visibility on initial orders from the MedX Brazilian distribution partner, that could result in $8 million of hardware sales over the next 2 years and a run-rate of $14 million of high margin, recurring platform revenue by the end of FY21. Given that MedX currently trades on a market cap of C$24 million, the C$14 million, if achieved, would mean MedX would trade on a 2022 market cap/sales ratio of only 1.7. Beacon Securities rates MedX Health a ‘buy’ with a Price Target of C$0.45. Given the stock currently trades at C$0.135, the C$0.45 price target represents a very significant upside of 233% or a 3.3 fold gain.

Closing remarks

It is very clear to me that the market is yet to wake up to the potential very large boost in revenues that MedX is working to achieve, now with distribution agreements in both Brazil and Mexico.

Detecting skin cancer is an enormous global need and MedX is working hard to fill this need. MedX has the right device and approvals in 35 countries. All that is needed now is further distribution agreements and revenue to flow. The opportunity for investors to get in early on such a great company with a very bright future still exists. I would not recommend waiting too long as the cheap valuation is unlikely to last long, especially as further new deals are announced.

Disclaimer/Disclosure: The InvestorIntel Sr. Editor Matthew Bohlsen currently owns shares in MedX Health Corp. The information in this article is general in nature and should not be relied upon as personal financial advice. For more information, contact Tracy Weslosky at [email protected]




Newly listed Perimeter Medical Imaging’s Andrew Berkeley on reducing the amount of repeat surgeries for cancer patients

“The holy grail for medical technologies is to improve patient care and to reduce cost to the healthcare system. That’s where Perimeter is entirely focused on. Our technology is aimed at giving surgeons the ability to remove cancer tumors during procedures more successfully and that reduces the amount of repeat surgeries for cancer patients. This in turn will reduce the cost to the payer who has to pay for these unnecessary operations.” States Andrew Berkeley, Business Development and Founder of Perimeter Medical Imaging AI, Inc. (TSXV: PINK), in an interview with InvestorIntel’s Tracy Weslosky.

Andrew went on to say that Perimeter’s trading symbol is PINK which references their passion in solving a very big problem in breast cancer which is the unnecessary and unwanted amount of repeat surgeries. He continued, “about one in four women who had breast cancer surgery will return to the operating room for a second surgery. We hope that using our imaging device and eventually with our AI component we will be able to drastically reduce the amount of unnecessary second operations”

In the interview Andrew provided an update on the receipt of a US$7.44 million grant from CPRIT, a leading state body funding cancer research. He said, “The grant is to fund the development of the AI platform. We will be working with the leading physicians and sites in the state of Texas to gather the data to train our algorithms and also to test the algorithm in a multi-site clinical trial”

To access the complete interview, click here

Disclaimer: Perimeter Medical Imaging AI, Inc. is an advertorial member of InvestorIntel Corp.




Drolet Stock Note: XPhyto Therapeutics — Medical Cannabis Meets Modern Sciences

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released his Stock Notes on XPhyto Therapeutics Corp. (CSE: XPHY) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on XPhyto Therapeutics Corp.:

  • XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets.
  • XPhyto and 3a are working to develop and commercialize a real-time, low-cost and easy-to-use oral screening test to concurrently detect COVID-19 and non-COVID-19 coronaviruses.
  • XPHY surge from $2.30 to 3.17 in the last month
  • XPHY traded over 5.5 Million shares between $2.10 & $3.50 over the last four months
  • Support: S2; $ 2.70   S1; $2.92   Resistance:   R1; $3.15   R2; $3.50

About XPhyto Therapeutics Corp.

XPhyto is a biopharma, diagnostics and cannabis science company focused on formulation, clinical validation, and European imports, distribution and sales. XPhyto’s 100% owned subsidiary, Vektor Pharma TF GmbH, a German narcotics manufacturer, importer and researcher has expertise in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips. Vektor also holds a number of narcotics licences issued by the German Federal Institute for Drugs and Medical Devices (BfArM), including import and manufacturing permits, as well as EU GMP lab certification. XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by BfArM. Bunker has two exclusive R&D collaboration agreements with the Technical University of Munich, Chair of beverage and brewing technology and the Faculty of Chemistry. XPhyto is pursuing additional opportunities in Europe including commercial cannabis cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability. XPhyto signed a supply, import and distribution agreement for cannabis oils and isolates with one of the largest, highest quality, and lowest cost cannabis cultivators in the world.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.




Perimeter Medical Imaging AI lists on the TSXV and offers surgeons real-time imaging to visualize the margins of cancer excised tissue

One of the biggest problems today in cancer treatments is determining during surgery if the operation has caught all of the cancer. Now a company has a solution. This is incredible news for cancer patients and health care providers. In 2020 roughly 1.8 million people will be diagnosed with cancer in the United States. This new technology is initially focused on breast cancer and during lumpectomy surgery, because approximately 1 in 4 patients return for a second surgery due to cancerous tissues being left behind. 2,000,000 women worldwide were diagnosed with breast cancer in 2018 and 317,000 in the USA in 2019.

This Company has a high definition and developing Artificial Intelligence (AI) imaging technology that can help surgeons identify if cancer is still present post-tumor removal surgery by examining the perimeter of the excised area.

The Company is aptly named Perimeter Medical Imaging AI Inc. (TSXV: PINK) (“Perimeter”) and the Company has only just listed this week on the TSX-V exchange. The stock ticker symbol, PINK, alludes to the pink ribbons used during breast cancer awareness month by the Canadian Cancer Society and the American Cancer Society, driving home the Company’s dedication to helping surgeons, radiologists and pathologists use Perimeter’s imaging technology and AI in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year. The raised capital from the public listing will be used for accelerating the commercialization process as well as refining the AI.

Perimeter Medical Imaging AI Inc. uses high definition imaging and AI in the fight to detect cancer at the perimeter

Source

Dr. Anthony Holler, the Chairman of Perimeter’s Board of Directors states:

“Perimeter’s platform imaging technology allows surgeons in real time to visualize the margins of excised tissue specimens at the time of surgery. With the combination of our high resolution imaging device and proprietary AI technology that is currently under development, the intention is to reduce the necessity of repeat surgeries. Our mission is to improve cancer patient care and reduce healthcare costs.”

As a sign of confidence in Perimeter’s technology on April 24 it was announced that Perimeter Medical Imaging received a $7.44 million Cancer Prevention and Research Institute of Texas (CPRIT) grant to further develop ImgAssist AI Technology at leading cancer centers in Texas. The funding granted by the CPRIT will support technology development that aims to decrease the re-operation rates for breast cancer patients.

Perimeter’s AI imaging technology is known as OTIS™ (Optical Tissue Imaging Console), a US FDA 510(k) cleared product. It is designed to provide real-time information during breast cancer surgery. The platform’s ability to deliver ultra-high resolution and sub-surface image volumes across the surface of the removed tissue allows surgeons to assess if they have achieved the successful removal of the entire tumor. Should a surgeon identify cancerous cells at the surface of the tissue, they can immediately remove additional tissue from the patient. The OTIS™ technology could lower the financial burden to the healthcare system and become a significant win for patients, taking away the additional physical and mental trauma caused by the necessity to repeat the surgery.

Perimeter already has strong industry support as shown by these two quotes:

Dr. Alastair Thompson, an internationally recognized Surgical Oncologist stated: “We need to work smarter to reduce the reoperation rates for breast conservation surgery. Using OTIS™ to scan the surface of the lumpectomy during surgery could be the key to ensuring complete surgery the first time around.”

Dr. Savitri Krishnamurthy, another principal investigator with over two decades of experience in Pathology, stated: “The new era of tissue imaging using optical imaging platforms such as the OTIS™ will bring revolutionary changes to breast surgery and breast pathology practice.”

Perimeter’s technology is initially focused on breast cancer. Breast cancer is a $30 billion worldwide problem, where approximately 25% of surgeries must be done again as bits of cancer are often left behind. Perimeter’s technology could save over $800 per patient and $16,000 per repeat surgery.

Beyond that there is a massive global market for breast and other cancers, especially when surgical removal is the treatment of choice. This means the potential market is enormous.

Perimeter’s technology has a $3.7 billion global addressable market

Source: Perimeter Corporate Overview Q2 2020

Perimeter’s business model involves a combination of capital equipment, consumable, and service contract revenues. Other similar med-tech companies typically trade on 3-9x revenue, so it will be interesting to see how Perimeter goes in the next year given they are now commercializing the technology. Following the recent capital raises the Company has ~$33 million to help commercialize the business, which the Company believes should be more than sufficient for the Company to become cash flow positive.

The Perimeter Board and Management are highly specialized and experienced. For example Chairman Anthony Holler MD has founded or been CEO of companies that were acquired for a total of $2.5 billion. CEO Tom boon has >30 years experience in medical imaging. CFO Jeremy Sobotta played roles of increasing seniority in deploying about $4 billion in capital in M&A from the acquirer side during his pre-Perimeter career at Stryker (NYSE: SYK – US$69 billion market cap) and Smith & Nephew (NYSE: SNN – US$17 billion market cap).

Perimeter Medical Imaging AI Inc. is run by a highly specialized and experienced team

Source

Closing remarks

Investors have a chance to invest very early and with a low market cap into Perimeter Medical Imaging AI Inc. due to the stock only listing yesterday. Perimeter suggest (page 19) that they have a first mover advantage and better technology than their competitors. Certainly the very significant support from the Cancer Prevention and Research Institute of Texas tends to confirm this. The niche application of perimeter imaging and AI is a ground breaking technology with a huge addressable market. The technology is also a win-win for both surgeons and patients as it lowers costs and potentially reduces repeat surgery. Management is highly experienced with an excellent past track record. Investors should be sure to check out Perimeter Medical Imaging as the potential upside looks to be very significant if the Company continues to progress well.




MI3 Tech Note on PreveCeutical Medical Inc. (CSE: PREV | OTCQB: PRVCF)

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on PreveCeutical Medical Inc. (CSE: PREV | OTCQB: PRVCF) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on PreveCeutical Medical Inc.:

  • PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
  • PreveCeutical has partnered with the University of Queensland in multiple research and development programs. Under the agreements, intellectual property and results arising from these programs will be owned by PreveCeutical.
  • PREV is gaining momentum following good set of news release …
  • PREV traded over 68 Million shares over the last three months between $0.01 & $0.06
  • Support: S2; $ 0.025  S1; $ 0.045  Resistance:   R1; $ 0.06  R2; $0.075

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences. The Company’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




Market mover Predictmedix offers COVID-19 mass screening and now — a telemedicine platform

As COVID-19 global cases move towards 10 million (currently 8.26 million) one company now offers COVID-19 mass screening using a revolutionary form of Artificial Intelligence (AI). The technology also works for infection screening, sobriety testing and various other medical conditions such as mental disorders (depression & dementia). Early adopters are companies wanting to safeguard their workers as well as healthcare operations wanting to keep their premises safe from COVID-19 infection. The technology is suitable for large scale screening by governments, law enforcement, healthcare, other organizations, and employers worldwide.

That company is Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF). Predictmedix has developed a disruptive AI technology that is leading the future in impairment detection and healthcare screenings. Predictmedix‘s AI powered products use facial, thermal, video and audio recognition technologies to determine when individuals are impaired or suffering from infectious disease or mental illness.

In the case of infection, the Predictmedix technology can screen and detect early signs such as temperature variances on the face and body, eye redness, coughing, sneezing, and other signs suggesting infection.

The potential applications are enormous. Imagine the impact this can have on COVID-19 detection, by putting Predictmedix’s mass screening technology in all public places. Combine this with further specific COVID-19 testing on those individuals that are picked up on mass screening and finally we have a chance to trace and stop the coronavirus.

One example of a COVID-19 entry screening that can use Predictmedix technology

Source: Predictmedix

It is still early days for Predictmedix, however given the pace of new contracts, the Company is likely to grow exponentially. Predictmedix collect payments based on a Software as a Service (SaaS) user based model. Clients pay a monthly fee based on volume of screenings per use case, providing Predictmedix with recurring monthly revenue and multi-year contracts.

Recent contracts and partnerships with Predictmedix

  • June 19, 2020 – Acquisition of Telemedicine platform – MobileWellbeing. Predictmedix to offer a fully integrated enterprise solution for healthcare along with workplace health, safety, and compliance.
  • June 4, 2020 – Sales contract for its COVID-19 screening technology for the Caribbean region. Caribbean Digital Media Academy (CDMA) will act as a distributor for Predictmedix technology for the Caribbean with a specific focus on government and hospitality sectors.
  • June 4, 2020 – Partnership with Max Healthcare for facial technologies leading to neurological diagnostics for mental health disorders. Max Healthcare is one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.
  • May 20, 2020Sales contract with Juiceworks Exhibits (events and exhibit marketing industry).
  • May 9, 2020 – Deployment of COVID-19 mass screening technology with Max Healthcare. 
  • April 22, 2020 – Launch of a Pilot with Hindalco Industries Ltd for its impairment detection AI technology.

What the experts are saying:

  • Kapil Raval (Director of Artificial Intelligence Business Development at Microsoft) – “The most interesting part is that Predictmedix focuses on AI solutions to problems that matter to all of us.”
  • Dr Navdeep Singh Nanda – “Predictmedix can make a huge impact on the current COVID19 pandemic as their technology is the need of the day not just now but also in the future as we deal with other infectious diseases.”
  • Dr Alexander Bardon (Emergency Physicia) – “There is not going to be a medical​ breakthrough such as a vaccine or drug that is going to solve the COVID19 problem in the near future. Our only effective strategy is the prevention of viral transmission. We have applied travel bans and physical distancing orders to our society as a whole. This has had a devastating impact on our economy and way of life. With AI we could be much more tactful in our approach.

Predictmedix is moving forward at an incredible pace landing several new contracts and even appointing Microsoft Director of Business Development AI Solutions, Kapil Raval, as the Chairman of their Advisory Board. What started as a technology to detect for impairment has grown to detect infection and other medical conditions. Predictmedix offers an incredibly simple, cheap, yet brilliant, way to mass test globally for COVID-19 in public places without inconveniencing people. They combine this with a simple SaaS revenue collection model.

For investors all the signs are there. Predictmedix already has brilliant technology, early adopters, new contracts, a massive near term demand for COVID-19 screening technology, and now a telemedicine platform to better connect patients and healthcare providers.

Predictmedix stock has been rising fast, but still has a market cap of only C$66 million. Don’t miss this one.